Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Current Opinion in Immunology Année : 2015

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors

Résumé

Cancer immunotherapy is a rapidly evolving field that offers a novel paradigm for cancer treatment: therapies focus on enhancing the immune system's innate and adaptive anti-tumor response. Early immunotherapeutics have achieved impressive clinical outcomes and monoclonal antibodies are now integral to therapeutic strategies in a variety of cancers. However, only recently have antibodies targeting innate immune cells entered clinical development. Innate immune effector cells play important roles in generating and maintaining antitumor immunity. Antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are important innate immune mechanisms for tumor eradication. These cytolytic processes are initiated by the detection of a tumor-targeting antibody and can be augmented by activating co-stimulatory pathways or blocking inhibitory signals on innate immune cells. The combination of FDA-approved monoclonal antibodies with innate effector-targeting antibodies has demonstrated potent preclinical therapeutic synergy and early-phase combinatorial clinical trials are ongoing.
Fichier non déposé

Dates et versions

hal-01104938 , version 1 (19-01-2015)

Identifiants

Citer

Cariad Chester, Aurelien Marabelle, Roch Houot, Holbrook E Kohrt. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Current Opinion in Immunology, 2015, Lymphocyte development and activation * Tumour immunology, 33, pp.1-8. ⟨10.1016/j.coi.2014.12.010⟩. ⟨hal-01104938⟩
127 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More